413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)

被引：1
|
作者：
Lio, Peter [1 ]
Eichenfield, Lawrence F. [2 ,3 ,4 ]
Marcoux, Danielle [5 ]
Lee, Wan-Ju [6 ]
Teixeira, Henrique D. [6 ]
Raymundo, Eliza M. [6 ]
Gamelli, Amy E. [6 ]
Grada, Ayman [6 ]
Hu, Xiaofei [6 ]
Irvine, Alan D. [7 ,8 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA
[2] Univ Calif San Diego, Dept Dermatol, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA
[4] Rady Childrens Hosp San Diego, San Diego, CA USA
[5] Univ Montreal, St Justine Univ Hosp Ctr, Dept Pediat, Div Dermatol, Montreal, PQ, Canada
[6] AbbVie Inc, N Chicago, IL USA
[7] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[8] Childrens Hlth Ireland, Dermatol, Crumlin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad162.033
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
413
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Lio, Peter
    Eichenfield, Lawrence F.
    Marcoux, Danielle
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Raymundo, Eliza M.
    Gamelli, Amy E.
    Grada, Ayman
    Hu, Xiaofei
    Irvine, Alan D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB178 - AB178
  • [2] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Silverberg, Jonathan I.
    Deleuran, Mette
    Gold, Linda S.
    Bunick, Christopher G.
    Hijnen, Dirk Jan
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Platt, Andrew M.
    Grada, Ayman
    Hu, Xiaofei
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
  • [3] Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Blauvelt, Andrew
    Ardern-Jones, Michael R.
    Bieber, Thomas
    Hong, Chih-Ho
    Chu, Chia-Yu
    Liu, Meng
    Yang, Yang
    Ladizinski, Barry
    Teixeira, Henrique D.
    Calimlim, Brian M.
    Thyssen, Jacob P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
  • [4] RAPID QUALITY-OF-LIFE IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)
    Eyerich, Kilian
    Lynde, Charles W.
    Calimlim, Brian M.
    Liu, Meng
    Ladizinski, Barry
    Warren, Richard B.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 34 - 34
  • [5] Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids in moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Blauvelt, A.
    Ardern-Jones, M. R.
    Bieber, T.
    Hong, C.
    Chu, C. -Y.
    Liu, M.
    Yang, Y.
    Ladizinski, B.
    Teixeira, H. D.
    Calimlim, B. M.
    Thyssen, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E117 - E118
  • [6] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
    Prajapati, Vimal H.
    Bunick, Christopher G.
    Eyerich, Kilian
    Gold, Linda Stein
    Galimberti, Fabrizio
    Calimlim, Brian
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Sancho, Cristina
    Grada, Ayman
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Rapid skin improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Simpson, Eric L.
    Warren, Richard B.
    Eichenfield, Lawrence F.
    Katoh, Norito
    Hu, Xiaofei
    Zeng, Jiewei
    Calimlim, Brian M.
    Tenorio, Allan R.
    Teixeira, Henrique D.
    De Bruin-Weller, Marjolein
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB167 - AB167
  • [8] Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Guttman-Yassky, Emma
    Irvine, Alan D.
    Silverberg, Jonathan I.
    Papp, Kim A.
    Paller, Amy S.
    Waterhouse, Brian
    Tenorio, Allan R.
    Ladizinski, Barry
    Chu, Alvina D.
    Liu, John
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB129 - AB129
  • [9] RAPID SYMPTOM AND SLEEP IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)
    Ardern-Jones, Michael R.
    Beck, Lisa A.
    Calimlim, Brian M.
    Zeng, Jiewei
    Chu, Alvina D.
    Prajapati, Vimal H.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 34 - 35
  • [10] Rapid skin improvement with upadacitinib with or without topical corticosteroids in moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Simpson, E. L.
    Warren, R. B.
    Eichenfield, L. F.
    Katoh, N.
    Hu, X.
    Zeng, J.
    Calimlim, B. M.
    Tenorio, A. R.
    Teixeira, H. D.
    De Bruin-Weller, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E119
12345